Open Beta
MetriLume

US marketsIOVA

SEC-sourced researchBeta

IOVA

IOVANCE BIOTHERAPEUTICS, INC.

Company comparison ↗

Data passport

CIK
0001425205
Exchange
Nasdaq
Business activity
— · SIC 2836
Financial inputs
6/6
Filing date
Oct 2, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2023: 1,189,000.0000 USD; December 2024: 164,070,000.0000 USD; December 2025: 263,502,000.0000 USD263.5M USD0 USD0December 2023December 2024December 2025
IOVA · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20231,189,000.0000Feb 24, 2026
December 2024164,070,000.0000Feb 24, 2026
December 2025263,502,000.0000Feb 24, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025263,502,000.0000-390,978,000.0000-302,408,000.0000913,170,000.0000214,587,000.0000Feb 24, 2026
December 2024164,070,000.0000-372,177,000.0000-352,977,000.0000910,426,000.0000200,021,000.0000Feb 24, 2026
December 20231,189,000.0000-444,037,000.0000-361,820,000.0000——Feb 24, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$263.5MDecember 2025Feb 24, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$164.07MDecember 2024Feb 24, 202610-K
Net incomeNetIncomeLoss-$390.98MDecember 2025Feb 24, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$302.41MDecember 2025Feb 24, 202610-K
Total assetsAssets$913.17MDecember 2025Feb 24, 202610-K
Total liabilitiesLiabilities$214.59MDecember 2025Feb 24, 202610-K

New filings

Explore methodology ↗